Get the Stockscreener App
7.46
2.47%
0.18
Aligos Therapeutics Inc stock is traded at $7.46, with a volume of 49,221.
It is up +2.47% in the last 24 hours and up +0.95% over the past month.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
See More
Previous Close:
$7.28
Open:
$7.21
24h Volume:
49,221
Relative Volume:
0.41
Market Cap:
$39.65M
Revenue:
$7.97M
Net Income/Loss:
$-75.74M
P/E Ratio:
-0.3072
EPS:
-24.2853
Net Cash Flow:
$-85.33M
1W Performance:
-18.29%
1M Performance:
+0.95%
6M Performance:
-71.09%
1Y Performance:
-43.70%
1-Day Range:
$7.01
$7.96
1-Week Range:
$7.01
$9.25
52-Week Range:
$3.76
$46.80
Aligos Therapeutics Inc Stock (ALGS) Company Profile
Name
Aligos Therapeutics Inc
Sector
Industry
Phone
(800) 466-6059
Address
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
Compare ALGS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALGS
Aligos Therapeutics Inc
|
7.46 | 44.52M | 7.97M | -75.74M | -85.33M | -24.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-24 | Initiated | H.C. Wainwright | Buy |
| Jan-06-23 | Upgrade | Jefferies | Hold → Buy |
| Jan-06-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-23-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-07-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-22 | Downgrade | Jefferies | Buy → Hold |
| Sep-09-21 | Initiated | SVB Leerink | Outperform |
| May-17-21 | Resumed | Piper Sandler | Overweight |
| Nov-10-20 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-10-20 | Initiated | JP Morgan | Overweight |
| Nov-10-20 | Initiated | Jefferies | Buy |
| Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Aligos Therapeutics Inc Stock (ALGS) Latest News
Is it too late to sell Aligos Therapeutics Inc.Early Entry Ideas with Momentum Potential - Newser
Analyzing drawdowns of Aligos Therapeutics Inc. with statistical toolsFree Real-Time Analysis With Entry Targets - Newser
What is Aligos Therapeutics Inc. company’s growth strategyEarnings Report Growth Plan For Smart Trading - jammulinksnews.com
News impact scoring models applied to Aligos Therapeutics Inc.Secure Entry Point Finder with Analysis - Newser
Does Aligos Therapeutics Inc. show high probability of reboundEntry and Exit Strategy for Swing Traders - Newser
How Aligos Therapeutics Inc. stock performs during market volatilityEarnings Based Stock Performance Forecast - Newser
Is Aligos Therapeutics Inc. a growth stock or a value stockStock Strategy Picks For 2025 - jammulinksnews.com
What are analysts’ price targets for Aligos Therapeutics Inc. in the next 12 monthsEntry Signal Growth Plan For Smart Trading - jammulinksnews.com
Why Aligos Therapeutics Inc. stock attracts strong analyst attentionFree Weekly Return Pick Forecast Reports - Newser
Volatility clustering patterns for Aligos Therapeutics Inc.Momentum Based Equity Trading Plans Reviewed - metal.it
Aligos Therapeutics (NASDAQ:ALGS) Will Have To Spend Its Cash Wisely - Yahoo Finance
Is it the right time to buy Aligos Therapeutics Inc. stockSwing Trade Report That Work - jammulinksnews.com
Best data tools to analyze Aligos Therapeutics Inc. stockSupport and Resistance Zone Summary Chart - Newser
Real time breakdown of Aligos Therapeutics Inc. stock performanceLow Risk Trade Timing with Analysis Metrics - Newser
Moving Average Trends for Aligos Therapeutics Inc. Stock: What They IndicateShort Term Momentum Based Trading Strategy - Newser
What data driven models say about Aligos Therapeutics Inc.’s futureSwing Trade Entry and Exit Point Analysis - Newser
Aligos Therapeutics to Announce 2nd Quarter 2025 Financial Results on August 6, 2025 - The Manila Times
Aligos Therapeutics, Inc. to Announce Second Quarter 2025 Financial Results on August 6, 2025 - Quiver Quantitative
Is Aligos Therapeutics Inc. Stock a Smart Buy in 2025 Investment Analysis InsideWatchlist Generator With Real-Time Entry - Newser
Published on: 2025-07-29 20:14:23 - metal.it
Chartists Watching For Breakout in Aligos Therapeutics Inc.Risk Adjusted Technical Entry Plan Gains Followers - metal.it
Is This the Dip to Buy in Aligos Therapeutics Inc.Real-Time Trade Insights Spark Market Reactions - metal.it
Is Aligos Therapeutics Inc. stock overvalued or undervaluedInvest confidently with expert support - jammulinksnews.com
Statistical indicators supporting Aligos Therapeutics Inc.’s strengthMarket Sentiment Tracker with Smart Alerts - Newser
How does Aligos Therapeutics Inc. generate profit in a changing economyOverwhelming profit margins - jammulinksnews.com
Aligos Therapeutics Inc. Stock Chart Analysis: Bullish or Bearish Pattern Forming Predictive Analytics for Equity Growth Potential - Newser
News impact scoring models applied to Aligos Therapeutics Inc. Daily Stock Watch Summary with Key Insights - Newser
What is the risk reward ratio of investing in Aligos Therapeutics Inc. stockAchieve rapid wealth accumulation with smart picks - jammulinksnews.com
What are the latest earnings results for Aligos Therapeutics Inc.Unlock your portfolio’s hidden potential - jammulinksnews.com
What makes Aligos Therapeutics Inc. stock price move sharplyMaximize portfolio growth with expert advice - jammulinksnews.com
Aligos Therapeutics Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingFree Low-Risk Investment Plans - Newser
Aligos Therapeutics Inc Stock (ALGS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):